Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The "Geographic Atrophy Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ...

New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Spinal Muscular Atrophy Treatment Market Size, Share & Industry Trends Analysis Report By Type, ...

Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Additional Data from Phase 2 ARCHER Trial Demonstrated Both Significant Vision ...

DUBLIN--(BUSINESS WIRE)--The "Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, Intrathecal), By Treatment (Gene Therapy, Drug), By ...

Please provide your email address to receive an email when new articles are posted on . Dec. 5 is World Geographic Atrophy Day, a new initiative that seeks to empower individuals with this advanced ...

ARCHER II is a global, randomized, double-masked, sham-controlled Phase 3 trial expected to enroll approximately 630 patients with geographic atrophy (GA) secondary to age-related macular degeneration ...